Data Highlight Expanding Use of (Ultra)
Hypofractionated Treatments, Benefits in Patient Care Made Possible
by the Precision and Accuracy of Accuray Technologies
SUNNYVALE, Calif., May 17, 2023
/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today
that new data presented at the European Society for Radiotherapy
and Oncology (ESTRO) meeting reinforces the benefits of the
company's CyberKnife® and TomoTherapy®
platforms, including the latest generation Radixact®
System. More than 55 abstracts highlighting Accuray technologies
were presented at the 2023 ESTRO annual congress held in
Vienna, Austria, from May 12 to May 16, 2023, building on existing
clinical evidence and supporting the systems' use to deliver
(ultra) hypofractionated radiation treatments for the precise and
personalized treatment of a wide range of cancers.
"Accuray is committed to advancing radiotherapy and providing
innovative, clinically relevant solutions that enable medical care
teams to easily deliver the most precise and accurate
hypofractionated treatments with confidence – and certainty – each
and every treatment session. The ESTRO data show our customers are
delivering shorter, more personalized, and more effective
treatments, helping to maximize the results patients want and
minimize the side effects they don't. We look forward to continuing
to partner with those involved in patient care, empowering them to
treat more patients, better and faster, than ever before," said
Suzanne Winter, president and CEO of
Accuray.
During the meeting, Accuray hosted a symposium titled "Advances
in Hypofractionation for Breast and Prostate Cancer" featuring
clinical experts who discussed the most recent – and promising –
clinical studies. Hypofractionated radiotherapy – the delivery of
higher doses of radiation over a small number of treatment sessions
– provides an efficient and effective treatment option for an
increasing number of indications and may improve patients' clinical
and financial experiences. The company also unveiled the
VitalHold™* breast package for the Radixact System. This new
functionality is designed to enable medical care teams to provide
an integrated and automated Deep Inspiration Breath Hold (DIBH)
solution using Surface Guided Radiation Therapy (SGRT) that
simplifies the delivery of ultra-precise treatments, enhancing the
safety and speed of care.
"The information sharing that takes place at meetings such as
ESTRO is focused on the same critical goal – improving patient
care. The breadth of data presented at this year's meeting
continues to provide compelling evidence supporting the unique
benefits of Accuray CyberKnife and TomoTherapy platforms and their
potential to optimize the way cancer is managed throughout the
continuum of the care journey," said Seth Blacksburg, M.D., MBA,
Chief Medical Officer at Accuray. "The precision and accuracy of
the systems, along with Synchrony® real-time tracking
and adaptation technology, enable effective treatments to be
completed in the shortest possible schedule, freeing up precious
time for those diagnosed with cancer to live their lives."
ESTRO Study Highlights: Advances in Patient Care
CyberKnife Platform for Prostate Cancer: The
CyberKnife platform offers an effective treatment option for
prostate tumors, of which move unpredictably during treatment, with
just five sessions required. Studies on CyberKnife stereotactic
body radiation therapy (SBRT) have shown its ability to:
- Effectively treat low-risk disease, preserving quality of life
and challenging other treatment alternatives. Study authors
concluded, "SBRT is a focused therapy that is feasible,
well-tolerated, and preserves quality of life. This innovative
robotized approach challenges other focused treatment alternatives
as well as active surveillance1."
- Provide a "safe and viable treatment option" for locally
recurrent prostate cancer after definitive radiotherapy, supported
by five years of median follow-up2.
- Offer a viable treatment option with mild toxicity for patients
experiencing prostate bed recurrence following
prostatectomy3.
CyberKnife® Platform for Metastatic
Diseases: The CyberKnife platform offers targeted
treatment that effectively manages challenging metastatic diseases,
often requiring fewer treatment sessions. In some cases, just one
treatment session is sufficient. Studies on CyberKnife stereotactic
radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
highlight the system's capabilities, including:
- Providing a feasible treatment option with excellent local
tumor control and minimal side effects for select patients with
more than 10 brain metastases4.
- Delivering ablative doses to target spinal metastases, ensuring
good local control and low rates of toxicity while protecting
critical organs5.
- Offering a viable treatment option for bone metastases,
characterized by low acute and late toxicities. A complete pain
response was achieved by patients experiencing
symptoms6.
Synchrony® Technology: The Accuray proprietary
Synchrony technology is unique in using image guidance during
radiation treatment delivery to detect motion and automatically
adapt and synchronize the radiation beam in real-time with the
movement of the target. Studies presented at ESTRO show:
- Synchrony with the Radixact® System allows a
reduction of the target area to be treated in lung cancer patients,
compared to a LINAC based technique without tumor tracking, with a
median beam-on time of less than 10 minutes7.
- Synchrony with the CyberKnife® platform is an option
for the treatment of inoperable pancreatic cancer, offering
promising overall survival (OS at 12 months was 35%) and an
excellent post radiotherapy toxicity profile8.
- The combination of the CyberKnife System and Synchrony provides
an effective and well-tolerated option for the treatment of
early-stage breast cancer in five sessions. Cosmesis was rated as
excellent by 84% and good by15% of patients9.
TomoTherapy® Platform for Total Marrow
Irradiation: The TomoTherapy platform, including the
next-generation Radixact System are the only devices to feature
helical radiation delivery and integrated CT imaging, providing
greater control of the radiation dose so it conforms precisely to
the tumor and helps minimize dose to healthy tissue. For example,
total marrow irradiation may be used before a bone marrow
transplant as part of the treatment regimen for certain types of
cancer, but it requires a high degree of precision and accuracy. A
study presented at ESTRO provides just one example of the benefits
of TomoTherapy delivered total marrow irradiation:
- Total marrow irradiation with TomoHelical™ in
combination with melphalan and autologous transplant provides good
results with minimal side effects in patients with relapsed
multiple myeloma10.
*VitalHold™ is 510(k) pending. VitalHold is not available for
sale in the USA. It is not CE
marked and availability is subject to regulatory clearance or
approval in some markets.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions to deliver radiation treatments
for even the most complex cases—while making commonly treatable
cases even easier—to meet the full spectrum of patient needs. We
are dedicated to continuous innovation in radiation therapy for
oncology, neuro-radiosurgery, and beyond, as we partner with
clinicians and administrators, empowering them to help patients get
back to their lives, faster. Accuray is headquartered in
Sunnyvale, California, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, Twitter, and YouTube.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, clinical applications,
clinical results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products; the company's ability to develop
new products or improve existing products to meet customers' needs;
the company's ability to anticipate or keep pace with changes in
the marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
May 8, 2023, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1
https://www.estro.org/Congresses/ESTRO-2023/1356/urology/15917/stereotacticfocusedradiotherapyforlow-riskprostate.
2
https://www.estro.org/Congresses/ESTRO-2023/1397/urology/12946/stereotacticreirradiationforlocallyrecurrentprosta.
3
https://www.estro.org/Congresses/ESTRO-2023/1356/urology/15916/stereotacticsalvageradiotherapyfor-prostate-redrel.
4
https://www.estro.org/Congresses/ESTRO-2023/1374/cns/15682/roboticstereotacticradiotherapyfor-10brainmetastas.
5
https://www.estro.org/Congresses/ESTRO-2023/1359/mixedsites-palliation/15825/stereotacticbodyradiotherapy-sbrt-forspinalmetasta.
6
https://www.estro.org/Congresses/ESTRO-2023/1359/mixedsites-palliation/15826/stereotacticbodyre-irradiationforbonemetastases.
7
https://www.estro.org/Congresses/ESTRO-2023/1361/optimisation-algorithmsandapplicationsforphotonand/15391/initialclinicalexperiencewithitv-freelungsabrusing.
8
https://www.estro.org/Congresses/ESTRO-2023/1386/rttserviceevaluation-qualityassuranceandriskmanage/14467/clinicaloutcomesfollowingstereotacticablativebodyr.
9
https://www.estro.org/Congresses/ESTRO-2023/1352/breast/15626/stereotacticapbiforearly-stagebreastcancer-3-yearo.
10
https://www.estro.org/Congresses/ESTRO-2023/1619/sarcoma-haematology/14387/phase1studyofescalatedtotalmarrowirradiationandmel.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-cyberknife-and-tomotherapy-platforms-featured-in-more-than-55-abstracts-presented-at-estro-2023-reinforcing-systems-versatility-efficiency-and-effectiveness-301826913.html
SOURCE Accuray Incorporated